Diagnostics

RIQAS Anti-SARS-CoV-2 Serology EQA Programme

With more than 50,000 laboratory participants in over 139 countries, RIQAS is the world’s largest EQA scheme. We are pleased to announce the plan to expand our programme list with the introduction of a new full RIQAS anti-SARS CoV-2 Serology EQA programme. Comprising IgG, IgM and total antibodies, this new full scheme supports both qualitative and quantitative reporting.

Convenience: Liquid, ready-to-use samples

Rapid report turnaround time

Commutable sample matrix reflects real samples thanks to 100% human plasma

Qualitative and quantitative reporting options

Reactive and non-reactive samples available

Allows for the comparison of different methodologies

RIQAS Anti-SARS-CoV-2 brochure

RIQAS Anti-SARS-CoV-2
New RIQAS Programme

Qnostics Respiratory Multiplex Controls
Unbiased, Independent Performance Assessment

 The Qnostics Respiratory Target Multiplex (RTX) Controls consist of 5 independent control products covering a total of 20 different respiratory microbes. Each RTX Control is a combination of 4 different microbes in a physiological transport media for multiplex applications. 

Qnostics offer whole pathogen based controls which will mimic the patient sample through the total extraction- and analysis process.

RTX controls are compatible with all commercial instrument platforms including rapid tests.

The RTX controls were designed for use with:

Cepheid Xpert® Xpress SARS-CoV-2/Flu/RSV assay o Only RTX1QC01 applicable
BIOFIRE® Respiratory Panel 2.1 plus
Qiagen QIAstat-Dx® Respiratory SARS-CoV-S Panel

Technote RTX Controls

Qnostics RTX Controls

QCMD SARS-CoV-2 Antigen Testing Pilot Programme to Assess Performance against an International Peer Group

 We are pleased to announce a new QCMD EQA pilot study for SARS-CoV-2 (COVID-19) Antigen testing.

Can be used on all testing platforms
Suitable also for point-of-care and rapid tests
Non-infectious samples
Smartphone app submission of results
On-line EQA management system
Comprehensive reports

Information request

SARS-CoV-2 Antigen Pilot study
QCMD SARS-CoV-2 antigen

Using Cancer Master 524 Target Panel for Molecular Characterization of  Biliary Tract Cancer

Publication

View the publication on predicting molecular features of chemotherapy and immunotherapy responses in advanced BTC´s using clinical sequencing.

The Cancer Master Panel provided:

  • Comprehensive molecular signature analysis
  • Comparable psTMB results versus exome TMB´s
  • Comparable cross-validation data of Celemics and competitor panels, using randomly selected samples

Cancer Master 524 targets

SARS-CoV-2 Independent Whole Pathogen Controls for Molecular Assays

Qnostics’ range of SARS-CoV-2 (SCV2) products are designed to support laboratories in the verification, validation, and performance monitoring of their SARS-CoV2 molecular assay. The product range contains whole inactivated SCV2 virus covering the entire viral genome in a transport medium containing background human cells. The SCV2 materials have been extensively characterised across a wide range of different molecular workflows / assays both commercial and in house currently in use.

The SCV2 product range are external quality controls and are independent of manufacturers’ kit controls. These reagents enable laboratories using them to monitor assay, equipment and operator performance on a day to day basis.

The SCV2 product range fulfils the requirements of a reference material as described in ISO 15189.

Qnostics SARS-CoV-2 Controls
Covid-19 quality controls

Acusera Independent Quality Control for SARS-CoV-2 Serology Assays

Comprising both reactive and non-reactive controls for Anti SARS-CoV-2 , the Acusera SARS-CoV-2 Antibody Control will support assay validation and routine performance monitoring of serological assays for COVID-19.  Conveniently supplied in a liquid ready-to-use format with a 30 day open vial stability, waste is kept to a minimum. As a true third party control, independent performance assessment is guaranteed.

Benefits

  • Liquid ready-to-use requiring no preparation
  • 100% human plasma providing a matrix similar to the patient sample
  • True third party control ensuring unbiased performance assessment
  • Reactive and non-reactive controls available
  • Open vial stability of 30 days at 2ºC to 8ºC
  • Suitable for use with Anti SARS-CoV-2 assays

Acusera Anti-Covid-19 Quality Control

Molecular Controls for Infectious Disease

New Respiratory Target Multiplex (RTX) Controls

The Qnostics RTX control range enables the requirements for testing strategies during the upcoming flu season to be met. The range covers the viral and bacterial pathogens responsible for an array of respiratory diseases in various patient cohorts, whilst discriminating cold and flu from COVID-19.

RTX Plus Q Control
Target Pathogen – Influenza A (H1N1), Influenza B (Victoria), RSV A, Coronavirus (SARS-CoV-2) 

RTX2 Q Control
Target Pathogen – Parainfluenza 1, Adenovirus 1, Mycoplasma pneumoniae, Coronavirus (OC43) 

RTX3 Q Control
Target Pathogen – Parainfluenza 2, Metapneumovirus (A2), Enterovirus (A16), Coronavirus (229E) 

RTX4 Q Control
Target Pathogen – Parainfluenza 3, Rhinovirus (16), Legionella pneumophila, Coronavirus (NL63) 

RTX5 Q Control for paediatric testing.
Target Pathogen – Parainfluenza 4, Adenovirus (14), RSV B, Enterovirus (D68) 

Independent Third-Party Serology Controls for Accurate and Reliable Results

Randox Infectious Disease Serology Controls

User-friendly: Liquid ready-to-use and multi-analyte based, reducing the number of different control tubes in the lab

High quality: Human plasma-based with clinically relevant measuring values, manufactured under strict conditions

Economical: 60 day open vial stability for reduced waste

Analytes:
Lyme Disease: positive and negative, IgG and IgM
ToRCH: IgG positive, IgM positive, negative

Epstein Barr Virus, EBV: positive
HIV
Hepatitis
HTLV
Syphilis

Extended Molecular Coronavirus Array

Evidence Investigator Semi-automated Compact Benchtop System without Compromising on the Volume of Samples Processed

The Molecular Coronavirus Array simultaneously detects five strains of coronavirus including the COVID-19 (SARS-CoV-2, 229E, NL63, OC43 and HKU1). The wider panel provides a more comprehensive respiratory screen enabling informed treatment decisions to be made.

The new test utilises Randox Biochip Technology, with results available for 54 patient samples in less than 5 hours.

Sample Type: Nasopharyngeal Swab, Sputum, BAL

Sample Volume Investigator: 5μl of Nucleic Acid required for PCR detection.

Reduce the Number of False Negatives in SARS-CoV-2 Detection

New 4X 1Step RT-qPCR Kit for Detection of <5 Copies per Reaction

The new 4X 1Step RT-qPCR Probe Kit from highQu increases detection sensitivity by allowing higher sample volumes to detect RNA in diluted samples. Up to 10 ul sample can be used in a 20 ul reaction in fast PCR protocols.
  • Successfully tested for SARS Co-V-2 Diagnostics
  • Ideal for multi-plex protocols
  • Reliable outcome in single-step RT-qPCR for low copy number detection
  • Robust 4x 1-step mastermix including a hotstart PCR polymerase, an extremely active reverse transcriptase, advanced RNAse inhibitor and PCR water
  • Compatible with all commonly used instrument platforms

Develop and Validate Detection Assays with Positive SARS-CoV-2 Control

Complete SARS-CoV-2 Transcriptome in RNA Fragments

siTOOLs Biotech SARS-CoV-2 positive control contains RNA fragments (120 – 2000 nt) covering 98% of the SARS-CoV-2 transcriptome. It is applicable in RT-PCR or LAMP detection assays.
Wide detection range: Real-time quantitative PCR analysis of SARS-CoV-2 positive control using primers against fragments ORF1ab #8, E and N showed good detection sensitivity across five log-dilutions.

Molecular Infectious Disease Testing

Kit-Independent, Third Party Controls

Qnostics controls from Randox Laboratories are independent 3rd party controls, specifically designed for molecular nucleic acid detection in infectious medicine testing.

Controls are based on whole pathogens, and designed to fully reflect the detection of patient samples.
You are able to assess the entire testing process from extraction though amplification and detection.
Easy-to-use; delivered in a liquid frozen format.
Manufactured to ISO 13485 quality standards.

Importance of 3rd party controls in molecular infectious disease testing

The following disease areas are covered:
Transplantation Associated Disease
Respiratory Infections Testing
Blood Borne Virus Testing
Sexually Transmitted Disease
Gastrointestinal Infections
Meningitis/Encephalitic (ME)
Fungal Infections

Clinical Toxicology

Emergency Drugs of Abuse Screening with Multiplex Technology

Evidence Multistat is an automated benchtop immunoanalyser, using multiplex technology to enable more data from a single sample.

Simultaneous detection of 21 classical, prescription and synthetic drugs in one single sample
Easy to operate; analytes are prefilled in ready-to-use cartridges
High quality data with well tested Biochip Array technology
Speed: 21 analytes are analysed in 20 min
Save samples: only 200 ul required for analysis

 

The Importance of 3rd Party Quality Controls in Clinical Analysis

Why Use Control Reagents from an Independent Manufacturer?

Randox true third party controls are manufactured independently from reagents and calibrators. The unique value assignment process employs thousands of independent laboratories ensuring statistically valid targets are available for multiple instruments and methods.
With a shelf life of up to four years, laboratories can ensure continuity of lot supply whilst enabling long term QC monitoring. The availability of multi-analyte, multi-instrument controls will reduce costs and preparation time, consolidating multiple instrument specific controls into a single control product.

The importance of 3rd party controls

 

LabLife Nordic AB

Rättarens väg 9
SE-182 34 Danderyd
SWEDEN
+46 8 755 39 14